Overview

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary efficacy of multiple ascending dose (MAD) of LY03003 following intramuscular injections.
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Treatments:
N 0437
Rotigotine